EP Patent

EP3823615A4 — COMPOSITIONS AND METHODS OF TREATMENT OF DISORDERS CHARACTERIZED BY ABERRANTE RAS/MAPK SIGNALING

Assigned to Duke University · Expires 2022-04-06 · 4y expired

What this patent protects

Patent listed against dabrafenib-mesylate.

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: EP3823615A4
Jurisdiction: EP
Classification: —
Expires: 2022-04-06
Drug substance claim: No
Drug product claim: No
Assignee: Duke University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.